EA200400565A1 - Конъюгаты химически модифицированного гормона роста человека - Google Patents

Конъюгаты химически модифицированного гормона роста человека

Info

Publication number
EA200400565A1
EA200400565A1 EA200400565A EA200400565A EA200400565A1 EA 200400565 A1 EA200400565 A1 EA 200400565A1 EA 200400565 A EA200400565 A EA 200400565A EA 200400565 A EA200400565 A EA 200400565A EA 200400565 A1 EA200400565 A1 EA 200400565A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemically modified
growth hormone
human growth
modified human
conjugates
Prior art date
Application number
EA200400565A
Other languages
English (en)
Other versions
EA008505B1 (ru
Inventor
Рори Ф. Финн
Уэй Лэйо
Нед Р. Сиджел
Original Assignee
Фармация Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Корпорейшн filed Critical Фармация Корпорейшн
Publication of EA200400565A1 publication Critical patent/EA200400565A1/ru
Publication of EA008505B1 publication Critical patent/EA008505B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Согласно настоящему изобретению предложен химически модифицированный гормон роста человека (hGH), полученный путем связывания водорастворимого полимера с белком. Химически модифицированный белок по настоящему изобретению может иметь намного более продолжительную активность hGH, чем активность немодифицированного hGH, что дает возможность снизить дозу и создать благоприятные условия режима введения.Отчет о международном поиске был опубликован 2003.08.21.
EA200400565A 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека EA008505B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (2)

Publication Number Publication Date
EA200400565A1 true EA200400565A1 (ru) 2005-06-30
EA008505B1 EA008505B1 (ru) 2007-06-29

Family

ID=23295870

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200700431A EA200700431A1 (ru) 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека
EA200400565A EA008505B1 (ru) 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200700431A EA200700431A1 (ru) 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека

Country Status (25)

Country Link
EP (1) EP1453859A2 (ru)
JP (2) JP2005525302A (ru)
KR (2) KR20050044858A (ru)
CN (1) CN1608079A (ru)
AP (1) AP2004003050A0 (ru)
AU (1) AU2002356990A1 (ru)
BR (1) BR0214451A (ru)
CA (1) CA2467731A1 (ru)
CO (1) CO5580794A2 (ru)
EA (2) EA200700431A1 (ru)
EC (1) ECSP045114A (ru)
GE (1) GEP20063860B (ru)
HR (1) HRP20040448A2 (ru)
HU (1) HUP0500997A2 (ru)
IL (1) IL162031A0 (ru)
IS (1) IS7268A (ru)
MA (1) MA27544A1 (ru)
MX (1) MXPA04004809A (ru)
NO (1) NO20042182L (ru)
OA (1) OA13063A (ru)
PL (1) PL374354A1 (ru)
RS (1) RS53104A (ru)
TN (1) TNSN04090A1 (ru)
WO (1) WO2003044056A2 (ru)
ZA (1) ZA200403907B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
ME00239B (me) * 2002-01-18 2011-05-10 Biogen Ma Inc Polimerna jedinjenja polialkilena i njihova upotreba
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
ES2897470T3 (es) 2002-09-09 2022-03-01 Nektar Therapeutics Alcanales poliméricos solubles en agua
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
CN100580087C (zh) * 2003-10-10 2010-01-13 诺和诺德医疗保健公司 肽的缀合
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
EP2368579A1 (en) * 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
CN103290084A (zh) * 2004-12-22 2013-09-11 Ambrx公司 表达和纯化重组人类生长激素的方法
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
CN103690936A (zh) * 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
EP1877439B1 (en) 2005-04-18 2011-02-09 Novo Nordisk A/S Il-21 variants
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
AU2006311568B2 (en) 2005-11-08 2010-11-11 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
US20080317670A1 (en) 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
KR20100014215A (ko) 2006-07-07 2010-02-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 신규 단백질 접합체 및 그것의 제조 방법
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CA2720306C (en) 2008-04-03 2016-03-15 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
KR101533757B1 (ko) * 2008-07-31 2015-07-03 파마이센시아 코퍼레이션 펩티드-중합체 접합체
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
EP2389389B1 (en) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stable growth hormone compounds
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
CN102711733A (zh) 2009-12-15 2012-10-03 阿森迪斯药物股份有限公司 瞬时连接于聚合物载体的干生长激素组合物
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
KR101813595B1 (ko) 2010-01-22 2017-12-29 노보 노르디스크 헬스 케어 악티엔게젤샤프트 장기적 생체 내 효능을 갖는 성장 호르몬
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
WO2016073825A1 (en) 2014-11-06 2016-05-12 Pharmaessentia Corporation Dosage regimen for pegylated interferon
ES2896971T3 (es) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
US20190290733A1 (en) * 2015-03-11 2019-09-26 Nektar Therapeutics Conjugates of an il-7 moiety and a polymer
RU2738416C2 (ru) * 2015-09-18 2020-12-14 Юниверсити Оф Миязаки Длительно действующее производное адреномедуллина
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2113354T3 (es) * 1990-05-04 1998-05-01 American Cyanamid Co Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69638117D1 (de) * 1995-09-21 2010-03-04 Genentech Inc Varianten des menschlichen Wachstumshormons
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
IL144259A0 (en) * 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
ATE246202T1 (de) * 1999-01-29 2003-08-15 Hoffmann La Roche Gcsf konjugate
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
JP2004524020A (ja) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス 改良された成長ホルモン分子

Also Published As

Publication number Publication date
EA200700431A1 (ru) 2008-02-28
HRP20040448A2 (en) 2006-02-28
PL374354A1 (en) 2005-10-17
KR20070072924A (ko) 2007-07-06
CA2467731A1 (en) 2003-05-30
EA008505B1 (ru) 2007-06-29
BR0214451A (pt) 2006-05-30
TNSN04090A1 (fr) 2006-06-01
MXPA04004809A (es) 2004-08-11
MA27544A1 (fr) 2005-10-03
ZA200403907B (en) 2007-12-27
WO2003044056A2 (en) 2003-05-30
CN1608079A (zh) 2005-04-20
NO20042182L (no) 2004-08-11
JP2005525302A (ja) 2005-08-25
ECSP045114A (es) 2004-07-23
WO2003044056A3 (en) 2003-08-21
OA13063A (en) 2006-11-10
GEP20063860B (en) 2006-06-26
KR20050044858A (ko) 2005-05-13
HUP0500997A2 (en) 2007-11-28
CO5580794A2 (es) 2005-11-30
AP2004003050A0 (en) 2004-06-30
EP1453859A2 (en) 2004-09-08
JP2006321808A (ja) 2006-11-30
AU2002356990A1 (en) 2003-06-10
IL162031A0 (en) 2005-11-20
IS7268A (is) 2004-05-17
RS53104A (en) 2006-10-27

Similar Documents

Publication Publication Date Title
EA200400565A1 (ru) Конъюгаты химически модифицированного гормона роста человека
CY1106723T1 (el) Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων
EA200300845A1 (ru) Модифицированные антитела и способы применения
EA200300856A1 (ru) Долгоживущие производные рилизинг-фактора гормона роста
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
CY1109786T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
EA200201214A1 (ru) Замещенные тиоацетамиды
DK1347730T4 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
BR0208183A (pt) Peptìdeo modificado por wt1
EA199900979A1 (ru) Композиции активированного протеина
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
IL141021A (en) Use of copolymer-like polypeptide-1 to prepare a drug to treat autoimmune diseases
DE60140426D1 (de) Pharmazeutische zusammensetzung für muskelanabolismus
EP2279752A3 (en) Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation
MXPA04000599A (es) Derivados del acido indan acetico y su uso como agentes pharmaceuticos, intermediarios, y metodo de preparacion.
EA200100905A1 (ru) Фармацевтическая композиция, содержащая ингибиторы протонного насоса
BR0316716A (pt) Conjugados quimicamente modificados do hormÈnio do crescimento humano
EP1891954A3 (en) Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
EP2962699A3 (en) Improved method for preparing conjugates of proteins and chelating agents
EA200300852A1 (ru) Конъюгаты нейбластина с полимерами и способы их применения
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение